The Zhitong Finance App learned that minimally invasive healthcare (00853) rose by more than 6% in the morning. As of press release, it had risen 6.05% to HK$7.36, with a turnover of HK$158 million.
According to the news, Minimally Invasive Healthcare announced that on July 15, 2026, the company's subsidiary Suzhou Minimally Invasive Orthopedic (Group) Co., Ltd. (Suzhou Minimally Invasive) signed a letter of intent with Beijing Tianzhihang Medical Technology Co., Ltd. (688277.SH). The details are that Tianzhihang may acquire controlling interests in the target company from Suzhou Minimally Invasive and Shanghai Minimally Invasive Orthopedic Medical Technology Co., Ltd. (along with its subsidiaries, the “Target Group”). The price will be paid by Tianzhihang's issuance of new shares.
As of the date of the letter of intent, the target company was 82.29% of the shares held by Suzhou Weichuang and registered as a subsidiary of the company. It is the core operator of the Group's international (non-Chinese) orthopedic business. The target group is mainly engaged in hip and knee orthopedic reconstruction business in overseas markets such as the United States, Japan, and Europe. The target group has been deeply involved in the field of orthopedics for many years, focusing on R&D, production and sales of high-quality innovative hip and knee products that have been fully clinically proven, and has a mature and large-scale overseas sales network. Its representative product, internal axle knee prosthesis, has accumulated more than 20 years of clinical application history. According to relevant research results published in The Knee Journal, the 17-year cumulative retention rate of the target group's internal axle knee prosthesis was as high as 98.8%, and patient satisfaction reached 95%.